Deutsche Multiple Sklerose Gesellschaft, Bundesverband e. V (DMSG)


Suche

Artikel MS FAQ MS Lexikon

Hauptnavigation 3.Ebene


Inhaltsbereich

Behandlungsleitlinien


Literaturliste Immunmodulatorische Stufentherapie der Multiplen Sklerose - I. Ergänzung: Dezember 2000

Literaturliste

1. Barkhof F, Filippi M, Miller D, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120: 2059-2069

2. Berg D, Mäurer M, Warmuth-Metz M, et al. The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis. Arch. Neurol. 2000; 57: 1289-1292

3. Brex PA, Jenkins R, Fox NC, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000; 54: 1689-1691

4. Brex PA, Miszkiel KA, O'Riordan JI, et al. Development of new lesions on serial T2-weighted MRI increases the risk of the early development of MS following a clinically isolated syndrome. J. Neurol. 2000; 247 Suppl3.: III-20

5. Brod SA, Lindsey JW and Wolinsky JS. Combination therapy with glatiramer acetate (Copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis. Ann. Neurol. 2000; 47: 127-131

6. Coles A, Wing M, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 1999; 46: 296-304

7. Comi G, Filippi M, Barkhof F, et al. Interferon beta 1a (Rebif) in patients with acute neurological syndromes suggestive of multiple sclerosis: A multi-center, randomized, double-blind, placebo-controlled study. Neurology 2000; 54 (Suppl. 3): A85-A86

8. Comi G, Filippi M and Copaxone Study Group. The effect of glatiramer acetate (Copaxone®) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): A multi-center, randomized, double-blind, placebo-controlled study extended by open label treatment. Neurology 1999; 52 (Suppl. 2): A 289

9. Deisenhammer F, Mayringer I, Harvey J, et al. A comparative study of the relative bioavailability of different nterferon beta preparations. Neurology 2000; 54: 2055-2060

10. Fazekas F, Barkhof F, Filippi M et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 1999; 53: 448-456

11. Freedman M and PRISMS Study Group. Long-term efficacy of interferon-beta 1a (Rebif) in relapsing-remitting MS: 4-years results of the PRISMS study. American Academy of Neurology 52nd Annual Meeting 2000; San Diego, USA

12. Optic  Neuritis Study Group. The 5-year risk of MS after optic neuritis. Neurology 1997; 49: 1404 1413

13. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. The Lancet 1998; 352: 1498-1504

14. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285

15. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS - Results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-465

16. Hartung H, Gonsette R and the Mitoxantrone in MS study group. Mitoxantrone in progressive multiple sclerosis (MS): A placebo-controlled, randomized, observer-blind European phase III multicenter study - clinical results. Multiple Sclerosis 1998; 4: 325.

17. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. New Engl. J. Med. 2000; 343: 898-904

17a. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefitsof glatiramer acetate in relapsing remitting multiple sclerosis patients observed for 6 years. Multiple Sclerosis 2000; 6: 255-266.

18. Liu C, Li Wan Po A and Blumhardt LD. Summary measure statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psych. 1998; 64: 726-729

19. Ludwin SK. Understanding multiple sclerosis: Lessons from pathology. Ann. Neurol. 2000; 46: 691-693

20. Mäurer M and Rieckmann P. Relapsing-remitting multiple sclerosis: What is the potential for combination therapy ? BioDrugs 2000; 13: 149-158

21. Mäurer M, Rieckmann P, Gold R and Toyka KV. Behandlung der schubförmigen Multiplen Sklerose (MS) mit rekombinanten Interferon-beta Präparaten: Aspekte zur Pharmakologie und Dosierung. Nervenarzt 2000; in press:

22. McFarland H and IFNb-1b SPMS-Study Group. Subcutaneous IFNbeta-1b in secondary progressive multiple sclerosis. 52nd Annual Meeting American Academy Neurology 2000; San Diego:

23. Morrisey S, Miller D and Kendall B. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Brain 1993; 116: 135-146

24. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. The Lancet 1998; 352: 1491-1497

25. Multiple Sklerose Therapie Konsensus Gruppe (MSTKG). Immunmodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt 1999; 70: 371-386

26. National Multiple Sclerosis society (NMSS). Disease management consensus statement. Internet: www.nmss.org 1998; 1: 4

27. Nortvedt MW, Riise T, Kjell-Morten M and Nyland HI. Quality of life in multiple sclerosis. Neurology 1999; 53: 1098-1103

28. Noseworthy J, Rodriguez M, Petterson T, et al. Multiple Sclerosis disease activity may determine whether immunoglobulin (IVIg) administration enhances or worsens visual function in patients with severe, stable optic neuritis (ON). Neurology 2000; 54 (Suppl. 3): A258

29. Noseworthy J, Gold R and Hartung HP. Treatment of multiple sclerosis: recent trials and future perspectives. Curr. Opin. Neurol 1999; 12: 279-293

30. Noseworthy JH, Wolinsky JS, Lublin FD, et al. Linomide in relapsing and secondary progressive MS. Neurology 2000; 54: 1726-1733

31. O'Riordan J, Thompson A, Kingsley D, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998; 121: 495-503

32. Oger J and Freedman M. Consensus statement of the Canadian MS clinics network on the use of disease modifying agents in mutiple sclerosis. Can. J. Neurol. Sci. 1999; 26: 294

33. Once weekly Interferon in MS Study Group (OWIMS). Evidence of interferon beta-1a dose response in relapsing-remitting multiple sclerosis. Neurology 1999; 53: 679-686

34. Paty DW and SPECTRIMStudy Group. Results of the 3-year, double-blind, placebo-controlled study of interferon beta-1a (Rebif) in secondary progressive MS. J. Neurol. 1999; 246 Suppl.1: I/15

35. Poser CM, Paty DW and Scheinberg L. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983; 13: 227-231

36. Pozzilli C, Pantano P, Caramia F, et al. Serial monthly MRI in early onset multiple sclerosis. Neurology 2000; 54 Suppl. 3: A119-A120

37. Reder AT and Antel JP. Injecting rationale into interferon-beta therapy. Neurology 2000; 54: 2034-2035

38. Rice GPA, Filippi M, Comi G et al. Cladribine and progressive MS. Neurology 2000; 54: 1145-1155

39. Rieckmann P, Toyka KV and Austrian, German, Swiss Multiple Sclerosis Therapy Consensus Group (MSTCG). Escalating immunotherapy of multiple sclerosis. Eur. Neurol. 1999; 42: 121-127

40. Rothwell PM, McDowell Z, Wong CK and Dorman PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 1997; 314: 1580-1583

41. Rudick R, Antel J, Confavreux C, et al. Recommendations from the national multiple sclerosis society clinical outcomes assessment task force. Ann. Neurol. 1997; 42: 379-382

42. Rudick R, Fisher E, Lee J, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999; 53: 1698-1704

43. Sailer M, o'Riordan JI, Thompson AJ, et al. Quantitative MRI in patients with clinically isolated syndromes of demyelination. Neurology 1999; 52: 599-606

44. Schwid SR and Noseworthy JH. Targeting immunotherapy in multiple sclerosis. Neurology 1999; 53: 444-445

45. Simon JH, Kinkel RP, Jacobs L, et al. A Wallerian degenration pattern in patients at risk for MS. Neurology 2000; 54: 1155-1160

46. Soderstrom M, Jin Y, Hillert J and Link H. Optic neuritis. Prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998; 50: 708-714

47. Stangel M, Boegner F, Klatt CH, et al. Placebo controlled pilot trial to study the remyelinating potential of intravenous imunoglobulins in multiple sclerosis. J. Neurol. Neurosurg. Psych. 2000; 68: 89-92

48. Steinman L. Multiple approaches to multiple sclerosis. Nature Med. 2000; 6: 15-16

49. Tubridy N, Ader HJ, Barkhof F, et al. Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled paralel groups. J. Neurol. Neurosurg. Psych. 1998; 64: 50-55

50. Weilbach FX and Gold R. Disease modifying treatments for multiple sclerosis. CNS Drugs 1999; 11: 133-157

51. Weinshenker B, O'Brien P, Petterson T, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886

52. Wiendl H, Neuhaus O, Kappos L and Hohlfeld R. Multiple Sklerose - Aktuelle Übersicht zu fehlgeschlagenen und abgebrochenen Therapiestudien. Nervenarzt 2000; 71: 597-610

Letzte Änderung: 31.10.2002

Artikel bewerten:

Artikel Top 20

Weitere Artikel zum Thema


Navigation Inhaltsboxen

MS - HELPLINE der DMSG

Haben Sie weitere Fragen zum Thema MS?

Oder haben Sie ein Problem, das sich im persönlichen Gespräch besser klären läßt?

Rufen Sie uns an!

Unter 01805 / 777 007 werden Sie mit kompetenten und unabhängigen DMSG -Mitarbeitern verbunden (0,14 € / Min. aus dem deutschen Festnetz und max. 0,42 € / Min. aus dem Mobilfunknetz).

Oder wählen Sie direkt Ihren Landesverband an!

Unabhängige, kompetente Mitarbeiter stehen Ihnen zur Seite.

MS- Wir lassen Sie nicht allein!

Logo MS-Helpline Logo HON-Code Logo DZI-Spendensiegel Logo DQS-Zertifikat
afgis-Qualitätslogo mit Ablauf 2012/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über DMSG Bundesverband e.V. und sein/ihr Internet-Angebot: www.dmsg.de

www.dmsg.de erfüllt die afgis-Transparenz-kriterien für hochwertige Gesundheitsinformationen im Internet.

Eine W3 WERK Produktion © DMSG 2014. Alle Rechte vorbehalten Impressum